1. Introduction {#sec1}
===============

Melanocortin receptors (MC3R and MC4R) have been demonstrated in multiple brain regions including the hypothalamus \[[@B1], [@B2]\] and represent critical components of a regulating system for body weight and energy homeostasis. Both disruption of MC4R in mice \[[@B3]\] and mutations in the coding region of human *MC4R* result in a severely obese phenotype \[[@B4], [@B5]\]. Another relatively rare (2--4%) polymorphism in the *MC4R* coding region has been reported to protect from obesity \[[@B6]\]. In recent genome-wide association studies (GWAS) also common genetic variants near the *MC4R* gene were associated with BMI \[[@B7]\], waist circumference, and insulin resistance \[[@B8]\].

Melanocortin receptors receive information from POMC and AgRP neurons about the nutritional and metabolic status. While POMC derivates like alpha-MSH and beta-MSH stimulate melanocortin receptors, agouti-related protein (AgRP) is known to be a natural antagonist. As leptin and insulin activate POMC neurons and suppress AgRP neurons, both hormones contribute to the regulation of body weight and energy homeostasis via melanocortin receptors, and knock-out of MC4R results in decreased action of leptin and insulin in the brain \[[@B9]\].

We previously established a method to measure acute insulin responses in the human brain by combining magnetoencephalography (MEG) and the hyperinsulinemic euglycemic clamp technique \[[@B10]\]. In this study, we observed that cerebral insulin resistance is associated with obesity in humans and therefore speculated that a decreased insulin response of the brain might contribute to obesity caused by genetic alterations of *MC4R*. As rs17782313 had the strongest BMI signal in a GWAS study \[[@B7]\], we studied the effect of this single nucleotide polymorphism (SNP) on the insulin response of the brain.

2. Methods {#sec2}
==========

2.1. Human Subjects and Experimental Design {#sec2.1}
-------------------------------------------

We determined rs17782313 in the *MC4R* gene region in 51 subjects who were healthy by self-report and clinical examination and presented nondiabetic in an oral glucose tolerance test according to WHO/ADA criteria. Detailed characteristics of these subjects are given in [Table 1](#tab1){ref-type="table"}.

2.2. Hyperinsulinemic Euglycemic Clamp and Saline Experiment with Measurement of Cerebrocortical Activity by Magnetoencephalography (MEG) {#sec2.2}
-----------------------------------------------------------------------------------------------------------------------------------------

To measure the insulin response of the brain, these subjects participated in an insulin and a placebo (=saline) experiment in random order on two different days approximately 1 to 2 weeks apart. Each experiment started at approximately 7.00 a.m. and consisted of a 30-minute baseline period, and a 2-step hyperinsulinemic euglycemic clamp or saline infusion. To maintain blood glucose at baseline levels a standard hyperinsulinemic euglycemic clamp protocol was followed. The details of the clamp procedures and the neurophysiologic measurements performed by MEG have been described in \[[@B10]\]. Here we used the change of spontaneous cortical beta and theta activity during insulin infusion (corrected for placebo derived changes) to quantify the cerebrocortical response to insulin. Beta and theta activity were extracted from spontaneous cortical activity by using fast Fourier transformation.

2.3. Analytical Procedures and Measurement of Body Fat {#sec2.3}
------------------------------------------------------

Plasma glucose was determined during the OGTT using the glucose oxidase method (YSI, Yellow Springs Instruments, Yellow Springs, CO, USA). Blood glucose was determined in the clamp experiments by a HemoCue blood glucose photometer (HemoCue AB, Aengelholm, Sweden). Plasma insulin levels were determined by microparticle enzyme immunoassay (Abbott Laboratories, Tokyo, Japan). Body composition was measured by bioelectrical impedance analysis (BIA-101A, RJL Systems, Detroit, Michigan, USA) and expressed as percent body fat.

2.4. Genotyping {#sec2.4}
---------------

For genotyping, DNA was isolated from whole blood using a commercial DNA isolation kit (NucleoSpin; Macherey & Nagel, Düren, Germany). The SNPs were genotyped using the TaqMan assay (Applied Biosystems, Foster City, CA). The TaqMan genotyping reaction was amplified on a GeneAmp PCR system 7000 (Applied Biosystems) (50°C for 2 minutes, 95°C for 10 minutes, followed by 40 cycles of 95°C for 15 seconds and 60°C for 1 minute), and fluorescence was detected on an ABI Prism sequence detector (Applied Biosystems). Quality control was performed as reported in \[[@B11]\].

2.5. Statistical Analysis {#sec2.5}
-------------------------

For statistical analyses, MEG data of the saline experiment were subtracted from data of the insulin experiment to correct for potential placebo effects and daytime variation. The change of the investigated MEG parameters from basal to the second step of the clamp was considered to indicate the total insulin effect and was used in further analyses.

Unless otherwise stated, data are means ± SE. Nonnormally distributed variables (Shapiro-Wilk W test) were logarithmically transformed. To adjust for covariates and to identify independent relationships, we performed linear multiple regression analyses. In general, a *P* value of \<.05 was considered to indicate statistical significance. As we studied insulin-induced changes in beta and theta activity, correction for multiple comparisons requires an alpha level of 0.025 instead of 0.05 for the primary analysis of MEG data. Due to the very low number of CC carriers, determination of a per allele risk as suggested by another study \[[@B7]\] was not possible. Therefore, TC and CC carriers were treated as one group and compared with wild-type carriers in all further analyses. For all statistical analyses, the software package JMP (SAS Institute, Cary, NC) was used.

2.6. Ethical Statement {#sec2.6}
----------------------

The study protocol was approved by the Ethical Committee of the University of Tübingen and informed written consent had been obtained from each subject prior to the studies. The whole study protocol has been designed in accordance with the declaration of Helsinki (1964). Furthermore, we certify that all applicable institutional and governmental regulations concerning the ethical use of human volunteers were followed during the research.

3. Results {#sec3}
==========

3.1. Genotype Data and Body Weight Effect of rs17782313 {#sec3.1}
-------------------------------------------------------

The genotype distribution (TT 30, TC 19, and CC 2) was in Hardy-Weinberg-Equilibrium, and the minor C-allele had a frequency of 23%. Carriers of the rare allele were 2.5 kg heavier, displayed a slightly increased BMI, waist circumference, and body fat as compared to the wild-type carriers; however, all these effects failed statistical significance ([Table 1](#tab1){ref-type="table"}). According to the weight effect, peripheral insulin sensitivity was reduced in CC carriers.

3.2. Cerebrocortical Insulin Resistance in Carriers of rs17782313 {#sec3.2}
-----------------------------------------------------------------

Regarding the effect of insulin on the cerebral cortex, we observed a decreased effect on theta activity ([Figure 1](#fig1){ref-type="fig"}) in presence of the C-allele (TT 33 ± 16 fT, TC/CC −27 ± 20 fT, *P* = .023). This association remained significant after adjusting for BMI (*P* = .038) and also after adjusting for BMI and peripheral insulin sensitivity (*P* = .047). In contrast to theta activity, there was no significant reduction of insulin-mediated beta activity by rs17782313 (TT 3.0 ± 3.2 fT, TC/CC −1.3 ± 4.1 fT, *P* = .41).

4. Discussion {#sec4}
=============

Our data demonstrate that the insulin response of the brain measured by magnetoencephalography (MEG) is diminished in carriers of rs17782313. From a mechanistical point of view, these data support the idea that a decreased insulin response of the brain is a pathogenic factor that contributes to the effect of this polymorphism on obesity. However, association data have some limitations, as they cannot definitely prove the direction of an effect and provide only indirect information on the underlying mechanisms. Here, it is clear that the primary site of the obesity effect must be located in the brain, as MC4R is highly expressed in the brain but not in peripheral tissues \[[@B1]\]. To get the best possible information from our data, we performed multiple regression models to adjust the cerebral effect of the polymorphism for obesity and for peripheral insulin resistance. As the SNP effect on the cerebrocortical insulin response remained significant, our data suggest that rs17782313 directly alters the insulin response of the brain.

In contrast to the cerebrocortical effect, the differences in obesity measures and metabolic parameters between the genotype group were not significant, though the effect size seems comparable to previous reports on *MC4R* polymorphisms \[[@B7], [@B8]\]. One explanation for the lack of significance in these parameters is that altered brain function is likely to be the primary effect of the *MC4R* SNP, while obesity and metabolic alterations are secondary. Furthermore, BMI and waist circumference have limited accuracy in small sample sizes.

We have previously demonstrated reduced insulin responses of beta and theta activities in obese humans \[[@B10]\]. Notably, the effect of rs17782313 occurred only in the theta activity band, while there was no effect on beta activity. In contrast, we observed that variation in the *FTO* and *IRS-1* gene is associated with a reduction of insulin-mediated beta activity, while theta activity is not affected \[[@B10], [@B12]\]. Furthermore, we reported that beta and theta activities are differently affected by aging \[[@B13]\] and suggested that these parameters may represent different brain structures and functions and their responses to insulin. Therefore, these data suggest that suppressed cerebral insulin effects by genetic variation in *FTO* and aging involve different mechanisms than variation in the *MC4R* gene.

It is interesting to note, that theta activity is mainly generated in the hippocampus \[[@B14]\]. Furthermore, the hippocampus has been shown to contribute to food-related reward in obese women \[[@B15]\]. Additionally, theta activity has been attributed to locomotor activity and voluntary movements \[[@B16]\]. Therefore, a decreased response of theta activity to insulin by the obesity risk allele of rs17782313 may indicate increased food reward and decreased locomotor activity as possible mechanisms that contribute to the development of obesity in these subjects.

5. Conclusions {#sec5}
==============

Genetic variation in *MC4R* leads to an impaired insulin response in theta activity in the human brain. Though specific suggestions on underlying brain functions are speculative, our data support that these functions may be different from alterations observed with aging and variation in the *FTO* gene.
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![Insulin effect on theta activity in the genotype groups**:**in subjects carrying the rare allele of rs17782313 in the homozygous (TC) or the heterozygous form (CC), the effect of insulin on theta activity was significantly reduced as compared to carriers of the wild-type allele (TT) (*P* = .023). The diamonds show the means of each group (horizontal line) and the confidence intervals of the means (upper and lower point). The effect of the genotype remained significant after adjusting for BMI (*P* = .038) and also after adjusting for BMI and peripheral insulin sensitivity (*P* = .047).](JOBES2011-283153.001){#fig1}

###### 

Subject characteristics and effect of rs17782313 on obesity measures and peripheral insulin sensitivity.

  Genotype                                                  TT              TC/CC           *P*
  --------------------------------------------------------- --------------- --------------- -------
  *N* (%)                                                   30 (59%)        21 (41%)        ---
  Gender (F/M)                                              14/16           12/9            ---
  Age (years)                                               33 ± 2          38 ± 3          .14
  Weight (kg)                                               81.4 ± 3.4      83.9 ± 3.6      .47\*
  BMI (kg/m²)                                               27.1 ± 0.9      28.4 ± 1.0      .62\*
  Body fat (%)                                              27.1 ± 1.6      30.5 ± 1.9      .57\*
  Waist circumference (cm)                                  92 ± 3          95 ± 3          .34\*
  Fasting plasma glucose (mmol/L)                           4.9 ± 0.1       5.1 ± 0.1       .35\*
  2 Hr glucose (mmol/L)\*\*                                 6.1 ± 0.3       6.6 ± 0.4       .51\*
  Insulin sensitivity index (*μ*mol·kg/^−1^·pM^−1^)\*\*\*   0.074 ± 0.009   0.062 ± 0.010   .67\*

M ± SE; \*adjusted for age and gender; \*\*OGTT; \*\*\*Hyperinsulinemic euglycemic clamp.
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